World Stroke Day 2018

MEDTRONIC YOUR STROKE CARE PARTNER

Providing solutions across
the Stroke Care Continuum

DO YOU KNOW THESE STROKE FACTS?1

 stoke facts

"We at Medtronic, are committed to improving the medical pathway of the stroke patient. Not only are we looking to constantly improve our fantastic devices, but we are also ensuring we take a broader look at the entire patient pathway, looking to implement improvements from start to finish."

Wilfred Van Zuilen, Vice President of Restorative Therapies Group, EMEA, Medtronic

STROKE SYMPTOMS

first signs of stroke

THE STROKE CARE CONTINUUM

SYSTEMS OF CARE

RAPID is the fastest and most advanced brain imaging technology, reducing image processing and analysis time to less than 2 minutes3.

Helping physicians facilitate:

  • Clinical decision making
  • Patient triage
  • Collaboration between community hospitals and specialists
  • Appropriate patient transfers to speciality centres

To enhance clinical workflow, the RAPID system provides immediate, automatically processed maps based on user-defined settings.

The RAPID neuroimaging platform is compatible with both MRI and CT imaging systems, creating real-time perfusion maps that allow physicians to easily interpret lesion volume.

IN-HOSPITAL WORKFLOWS

POST-STROKE MONITORING

 crytogenic stroke patient

Patients with atrial fibrillation (AF) are 5-times more likely to have a stroke4.

Undiagnosed AF is believed to cause a significant portion of cryptogenic strokes, so recognising and treating AF is key5 .

Since AF is mostly asymptomatic and infrequent6, it may not be detected by short-term, external heart monitors7.

The Reveal LINQTM Insertable Cardiac Monitoring System (ICM) transforms your ability to diagnose AF with its proven AF detection algorithm.

With up to 3 YEARS of continuous cardiac monitoring.

Reduce post-stroke spasticity

SPASTICITY IS A BURDEN ON PATIENTS, CAREGIVERS AND PAYERS

ITB IS AN EFFECTIVE THERAPY TO REDUCE SPASTICITY

ITB therapySM has been proven to significantly reduce spasticity in both lower and upper limbs, as measured by (modified) Ashworth scale (-1.5 and -1.0, p<0.01) after one year of treatment.14,15

ITB therapySM is proven to significantly improve function and quality of life of patients (p<0.05).14,15

improvement of patient function

ITB therapySM improves muscle strength in the spasticity-affected limbs and does not alter the strength in the unaffected limbs.14,15

73% of patients are satisfied with spasticity reduction and would recommend the therapy.16

ITB THERAPYSM IS SUPERIOR TO ORAL MEDICATION

ITB therapySM shows superior efficacy in reducing spasticity of lower and upper limbs vs. oral antispasticity medication as measured by Ashworth scale. Lower -1 vs. -0.4 CMM; upper -0.7 vs. -0.2 CMM (p<0.05).17

1

Wilkins E, Wilson L, Wickramasinghe K, et al. European Cardiovascular Disease Statistics 2017 edition. Eur Hear Network, Brussels. 2017:192. doi: 978-2-9537898-1-2.

2

King's College London for the Stroke Alliance for Europe (SAFE). The burden of stroke in Europe. The challenge for policy makers. 2017.

3

Friederike Austein, MD et al. Comparison of Perfusion CT Software to Predict the Final Infarct Volume After Thrombectomy. Aug 16 2017.

4

Wolf PA, et al. Arch Intern Med. 1987;147:1561-1564.

5

Stroke Prevention in Atrial Fibrillation Study. Circulation. 1991;84:527-539.

6

Sanna T, et al. N EnglJ Med. 2014;370:2478-2486.

7

Choe et al. A comparison of atrial fibrillation monitoring strategies after cryptogenic stroke (from the CRYSTAL AF trial). Am J Cardiol. 2015;116:889-93.

8

Ivanhoe CB, Francisco GE, McGuire JR, et al. Intrathecal baclofen management of poststroke spastic hypertonia: Implications for function and quality of life. Arch Phys Med Rehabil. 2006;87(11):1509-15.

9

Schiess MC, Oh IJ, Stimming EF, et al. Prospective 12-month study of intrathecal baclofen therapy for poststroke spastic upper and lower extremity motor control and functional improvement. Neuromodulation. 2011;14(1):38–45.

10

Gillard PJ, Sucharew H, Kleindorfer D, et al. The negative impact of spasticity on the healthrelated quality of life of stroke survivors: a longitudinal cohort study. Health Qual Life Outcomes. 2015;13:159. doi:10.1186/s12955-015-0340-3.D.

11

Welmer et al. Spasticity and Its association with functioning and health-related quality of life 18 months after stroke. Cerebrovasc Dis 2006;21:247–53.

12

Denno MS, Gillard PJ, Graham GD, et al. Anxiety and depression associated with caregiver burden in caregivers of stroke survivors with spasticity. Arch Phys Med Rehabil. 2013;94(9):1731–6. doi: 10.1016/j.apmr.2013.03.014.

13

Lundström E, Smits A, Borg J, Terént A. Four-fold increase in direct costs of stroke survivors with spasticity compared with stroke survivors without spasticity: the first year after the event. Stroke. 2010 Feb;41(2):319–24. doi: 10.1161/STROKEAHA.109.558619.

14

Ivanhoe CB, Francisco GE, McGuire JR, et al. Intrathecal baclofen management of poststroke spastic hypertonia: Implications for function and quality of life. Arch Phys Med Rehabil. 2006;87(11):1509-15.

15

Schiess MC, Oh IJ, Stimming EF, et al. Prospective 12-month study of intrathecal baclofen therapy for poststroke spastic upper and lower extremity motor control and functional improvement. Neuromodulation. 2011;14(1):38–45

16

Creamer et al. Effect of intrathecal baclofen on pain and quality of life in poststroke spasticity: A randomized trial (SISTERS). Stroke. 2018;49:2129–2137.

17

Creamer M, Cloud G, Kossmehl P, et al. Intrathecal baclofen therapy versus conventional medical management for severe post-stroke spasticity: Results from a multicentre, randomised, controlled, open-label trial (SISTERS). J Neurol Neurosurg Psychiatry. 2018 Jun;89(6):642-650.

*     Reveal LINQ™ ICM has been demonstrated to pose no known hazards in a specified MR environment with specified conditions of use. Please see Reveal LINQ™ clinician manual for more details.

RAPID is a CE marked software, developed by the iSchemaView.

Indications, Safety, and Warnings

See the device manual for detailed information regarding the instructions for use, the implant procedure, indications, contraindications, warnings, precautions, and potential adverse events. If using an MRI SureScan® device, see the MRI SureScan® Technical manual before performing an MRI. For further information, contact your local Medtronic representative and/or consult the Medtronic website at www.medtronic.com.

www.medtronic.com/manuals

www.medtronic.com/manuals

Consult instructions for use at this website. Manuals can be viewed using a current version of any major Internet browser. For best results, use Adobe Acrobat Reader® with the browser.

Important Reminder: This information is intended only for users in markets where Medtronic products and therapies are approved or available for use as indicated within the respective product manuals. Content on specific Medtronic products and therapies is not intended for users in markets that do not have authorization for use.

Medtronic and the Medtronic logo are trademarks of Medtronic™. * Third party brands are trademarks of their respective owners. All other brands are trademarks of a Medtronic company.